Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Sony Group Corp — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Sony Group Corp trades at $24.51 (market cap $140.46B). The key difference: Sony Group Corp is far larger — about 49.1× Dyne Therapeutics Inc. Common Stock's market cap, and Sony Group Corp pays a 0.65% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Sony Group Corp for 96 Days on average.
| DYN | SONY | |
|---|---|---|
Market Cap | $2.86B | $140.46B |
Volume | 3,341,579 | 5,764,125 |
Sector | Health | Technology |
52-Week High | $26.78 | $30.26 |
52-Week Low | $14.60 | $19.32 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $2.18B | $138.37B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Sony trades at $24.36, up 0.41% with a bullish technical signal from moving averages. The company reported strong Q4 2025 and Q2 2026 earnings beats, though Q1 2026 missed expectations. Revenue remains stable around $12.96T with improving operating cash flow of $2.32T. Analyst sentiment is strongly positive with 11 buy ratings and no sell recommendations, while recent news highlights Sony's content moat and AI litigation developments.
Sony presents a compelling investment case with solid fundamentals and strong analyst support, though negative net income margin and ROE raise concerns. The stock's valuation appears reasonable with P/E of 20.65 and EV/EBITDA of 8.05. Key risks include content competition and AI-related legal challenges, while opportunities lie in Sony's entertainment ecosystem and strategic expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
